CN101607059B - Application of Chinese medicinal composition in preparing medicament for treating and preventing radiation injury - Google Patents
Application of Chinese medicinal composition in preparing medicament for treating and preventing radiation injury Download PDFInfo
- Publication number
- CN101607059B CN101607059B CN200810055211XA CN200810055211A CN101607059B CN 101607059 B CN101607059 B CN 101607059B CN 200810055211X A CN200810055211X A CN 200810055211XA CN 200810055211 A CN200810055211 A CN 200810055211A CN 101607059 B CN101607059 B CN 101607059B
- Authority
- CN
- China
- Prior art keywords
- radix
- processed
- application
- fine powder
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention provides application of a Chinese medicinal composition in preparing a medicament for treating and preventing a radiation injury. The Chinese medicinal composition achieves the functions of improving the immunity of the organism and strengthening the spleen and tonifying the kidney by using all medicaments together, and achieves the aim of treating both the symptoms and root causes by clearing heat and releasing toxin and tonifying Qi and blood.
Description
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in the medicine of preparation treatment and prevention radiation injury, belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Ionizing radiation (like X line, neutron, proton, α or beta-particle, gamma-rays) can be directly or through secondary reactions damaging tissue.High dose radiation can produce visible health effect in a couple of days.DNA due to the low dose changes can make illuminated person produce chronic disease, makes their offspring's developmental genetics defective. and the healing of degree of injury and cell or the relation between the death are very complicated.
Deleterious ionized radiation source comprises and is used to high energy X line, radium and other naturally occurring radioactive substances (like radon), nuclear reactor, cyclotron, linear accelerator, the variable gradient synchrotron diagnosing and treat, be used to treat cancerous protuberance sealing cobalt and caesium and be used for medical science in a large number and radioactive substance that the manual work of industry produces.
After sufficiently high dose irradiation, necrocytosis can take place.High sublethal dose can be through reducing the mitosis rate, and it is synthetic or make cell become polypoid to slow down DNA, and the propagation of interference cell.The tissue that upgrades continuously (like enteric epithelium, bone marrow, gonad) can produce dose-dependent carrying out property hypoplasia, atrophy, final fibrosis after radiation.Some is impaired but still can carry out mitotic cell, before its death, also can produce unusual offspring (like huge metamyelocyte, the over-drastic neutrophil of leaflet) through 1 or 2 reproductive cycle.Report that it is long that the animals survived time ratio that other adds very low dose irradiation is only accepted time-to-live of animal of background exposure.
People are seeking radioprotectant for a long time, are not used to treat and prevent the toxic and side effects due to the radiation but find out an ideal medicine so far yet.
Theory of Chinese medical science thinks that lonizing radiation belong to the heresy of pyretic toxicity, after receiving RADI, is prone to cause body body fluid impaired, and pyretic toxicity is crossed Sheng.Disharmony between QI and blood, taste imbalance and caused by liver and kidney deficiency appear in severe patient.Xerostomia, pharyngalgia, mucous membrane of oropharynx and skin ulceration can appear, symptoms such as tired power, spontaneous perspiration.Therefore, to the toxicity due to the ray moisturize to promote the production of body fluid, heat-clearing and toxic substances removing, help that cold fills blood, medicine among the nourishing the liver and kidney.
Chinese patent 02146571.1 discloses a kind of pharmaceutical composition and method for preparing of human body immunity improving function.The application of unexposed this medicine composite for curing of this patent and prevention radiation damage, the present invention have been done further research back and have been confirmed that Chinese medicine composition of the present invention has good curing and improvement effect to radiation damage on the basis of this patented technology.
Summary of the invention
The present invention provides the application of a kind of Chinese medicine composition in the medicine of preparation treatment and prevention radiation injury, pharmaceutical composition strengthening vital QI to eliminate pathogenic factors of the present invention, and the human body immunity improving function, strengthening spleen, tonifying kidney reaches treating both the principal and secondary aspects of a disease.Show through test, pharmaceutical composition of the present invention be used to treat radiation according to due to toxicity; Can effectively reduce mortality of mice behind the lethal dose irradiation with radiation, improve life quality; Can not offset the killing effect of radiation, on the contrary, the synergistic antitumor effect arranged with radiation to tumor cell; Bone marrow and hepatic and renal function there is not any toxicity damage.
Acute toxicity test in mice shows that the clinical consumption of pharmaceutical composition of the present invention is 6g/ day, and the oral maximum tolerated dose of mice is 20.0g/kg, 232.6 times of the clinical consumption that is equivalent to be grown up, animal Non Apparent Abnormality and death.Long term toxicity test shows: the present invention does not all have obvious influence to biochemical indicators such as the general situation of rat, body weight, hemogram and main organs coefficient.
Technical scheme of the present invention is achieved in that
Medicine of the present invention is to be processed by the crude drug of following weight portion ratio:
Radix Astragali 130-390 part, Fructus Ligustri Lucidi 105-315 part, Radix Ginseng 39-117 part, Ganoderma 40-120 part, Rhizoma Curcumae 79-327 part, Herb Gynostemmae Pentaphylli 157-473 part, Rhizoma Atractylodis Macrocephalae (parched) 40-120 part, Poria 40-120 part, Cordyceps 5-15 part, Radix Cynanchi Paniculati 79-237 part, Eupolyphaga Seu Steleophaga 40-120 part, Radix Notoginseng 13-39 part, Herba Hedyotidis Diffusae 79-237 part, Herba Scutellariae Barbatae 79-237 part, Massa Medicata Fermentata preparata 25-75 part.
Preferably, medicine of the present invention is to be processed by the crude drug of following weight portion ratio:
260 parts of the Radixs Astragali, 210 parts of Fructus Ligustri Lucidi, 78 parts of Radix Ginsengs, 80 parts of Ganodermas, 158 parts of Rhizoma Curcumae, 315 parts of Herb Gynostemmae Pentaphylli, 80 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 80 parts in Poria, 10 parts of Cordyceps, 158 parts of Radix Cynanchi Paniculatis, 80 parts of Eupolyphaga Seu Steleophagas, 26 parts of Radix Notoginseng, 158 parts of Herba Hedyotidis Diffusaes, 158 parts of Herba Scutellariae Barbataes, 50 parts of Massa Medicata Fermentata preparatas.
Or:
130 parts of the Radixs Astragali, 3 15 parts of Fructus Ligustri Lucidi, 39 parts of Radix Ginsengs, 120 parts of Ganodermas, 79 parts of Rhizoma Curcumae, 473 parts of Herb Gynostemmae Pentaphylli, 40 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 120 parts in Poria, 5 parts of Cordyceps, 237 parts of Radix Cynanchi Paniculatis, 40 parts of Eupolyphaga Seu Steleophagas, 39 parts of Radix Notoginseng, 79 parts of Herba Hedyotidis Diffusaes, 237 parts of Herba Scutellariae Barbataes, 25 parts of Massa Medicata Fermentata preparatas.
Or:
390 parts of the Radixs Astragali, 105 parts of Fructus Ligustri Lucidi, 117 parts of Radix Ginsengs, 40 parts of Ganodermas, 327 parts of Rhizoma Curcumae, 157 parts of Herb Gynostemmae Pentaphylli, 120 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 40 parts in Poria, 15 parts of Cordyceps, 79 parts of Radix Cynanchi Paniculatis, 120 parts of Eupolyphaga Seu Steleophagas, 13 parts of Radix Notoginseng, 237 parts of Herba Hedyotidis Diffusaes, 79 parts of Herba Scutellariae Barbataes, 75 parts of Massa Medicata Fermentata preparatas.
The present invention also provides the active component of this medicine to be processed by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Cordyceps, Radix Notoginseng pulverize separately become fine powder, sieving for standby;
(3), the Radix Astragali, Fructus Ligustri Lucidi, Ganoderma, Rhizoma Curcumae, Herb Gynostemmae Pentaphylli, Rhizoma Atractylodis Macrocephalae (parched), Poria, Radix Cynanchi Paniculati, Eupolyphaga Seu Steleophaga, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Massa Medicata Fermentata preparata decocte with water twice, 2 hours for the first time, 1 hour for the second time; Merging decoction liquor filters; Filtrating concentrates, and drying is ground into dried cream powder;
Step (2) gained fine powder and step (3) gained dried cream powder constitute the active ingredient of Chinese medicine composition of the present invention jointly.
The dosage form of medicine of the present invention is capsule, tablet, powder, oral liquid, soft capsule, pill, tincture, syrup, suppository, gel, spray or injection.
The dosage form of medicine of the present invention adopts conventional method for preparing preparation, and for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record processes the acceptable regular dosage form of pharmaceutics.
For above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
The present invention also provides the method for preparing of this medicine capsule, and it is made up of following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Cordyceps, Radix Notoginseng pulverize separately become fine powder, sieving for standby;
(3), the Radix Astragali, Fructus Ligustri Lucidi, Ganoderma, Rhizoma Curcumae, Herb Gynostemmae Pentaphylli, Rhizoma Atractylodis Macrocephalae (parched), Poria, Radix Cynanchi Paniculati, Eupolyphaga Seu Steleophaga, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Massa Medicata Fermentata preparata decocte with water twice, 2 hours for the first time, 1 hour for the second time; Merging decoction liquor filters; Filtrating concentrates, and drying is ground into dried cream powder;
(4), with the dried cream powder facing-up of step (2) gained fine powder and step (3) gained, the mixing that sieves, encapsulated, promptly get.
The specific embodiment
Below in conjunction with the instance of drug regimen of the present invention, the specific embodiment of the present invention is described.
Embodiment 1:
Radix Astragali 260g Fructus Ligustri Lucidi 210g Radix Ginseng 78g Ganoderma 80g Rhizoma Curcumae 158g Herb Gynostemmae Pentaphylli 315g Rhizoma Atractylodis Macrocephalae (parched) 80g Poria 80g Cordyceps 10g Radix Cynanchi Paniculati 158g Eupolyphaga Seu Steleophaga 80g Radix Notoginseng 26g Herba Hedyotidis Diffusae 158g Herba Scutellariae Barbatae 158g Massa Medicata Fermentata preparata 50g.
Method for preparing:
(1), according to the recipe quantity side of taking by weighing Chinese crude drug, clean;
(2), Radix Ginseng, Cordyceps, Radix Notoginseng pulverize separately become fine powder, sieving for standby;
(3), the Radix Astragali, Fructus Ligustri Lucidi, Ganoderma, Rhizoma Curcumae, Herb Gynostemmae Pentaphylli, Rhizoma Atractylodis Macrocephalae (parched), Poria, Radix Cynanchi Paniculati, Eupolyphaga Seu Steleophaga, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Massa Medicata Fermentata preparata decocte with water twice, 2 hours for the first time, 1 hour for the second time; Merging decoction liquor filters; Filtrating concentrates, and drying is ground into fine powder;
(4), with the dried cream powder facing-up of step (2) gained fine powder and step (3) gained, the mixing that sieves is processed 1000 capsules, promptly gets.The clinical consumption of capsule of the present invention is 6g/ day.
Embodiment 2:
Radix Astragali 130g Fructus Ligustri Lucidi 315g Radix Ginseng 39g Ganoderma 120g Rhizoma Curcumae 7g Herb Gynostemmae Pentaphylli 473g Rhizoma Atractylodis Macrocephalae (parched) 40g Poria 120g Cordyceps 5g Radix Cynanchi Paniculati 237g Eupolyphaga Seu Steleophaga 40g Radix Notoginseng 39g Herba Hedyotidis Diffusae 79g Herba Scutellariae Barbatae 237g Massa Medicata Fermentata preparata 25g
Method for preparing:
(1), according to the recipe quantity side of taking by weighing Chinese crude drug, clean;
(2), Radix Ginseng, Cordyceps, Radix Notoginseng pulverize separately become fine powder, sieving for standby;
(3), the Radix Astragali, Fructus Ligustri Lucidi, Ganoderma, Rhizoma Curcumae, Herb Gynostemmae Pentaphylli, Rhizoma Atractylodis Macrocephalae (parched), Poria, Radix Cynanchi Paniculati, Eupolyphaga Seu Steleophaga, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Massa Medicata Fermentata preparata decocte with water twice, 2 hours for the first time, 1 hour for the second time; Merging decoction liquor filters; Filtrating concentrates, and drying is ground into fine powder;
(4), with the dried cream powder facing-up of step (2) gained fine powder and step (3) gained, the mixing that sieves is processed 1000 tablets of tablets by conventional method, promptly gets.
Embodiment 3:
Radix Astragali 390g Fructus Ligustri Lucidi 105g Radix Ginseng 117g Ganoderma 40g Rhizoma Curcumae 327g Herb Gynostemmae Pentaphylli 157g Rhizoma Atractylodis Macrocephalae (parched) 120g Poria 40g Cordyceps 15g Radix Cynanchi Paniculati 79g Eupolyphaga Seu Steleophaga 120g Radix Notoginseng 13g Herba Hedyotidis Diffusae 237g Herba Scutellariae Barbatae 79g Massa Medicata Fermentata preparata 75g
Method for preparing:
(1), according to the recipe quantity side of taking by weighing Chinese crude drug, clean;
(2), Radix Ginseng, Cordyceps, Radix Notoginseng pulverize separately become fine powder, sieving for standby;
(3), the Radix Astragali, Fructus Ligustri Lucidi, Ganoderma, Rhizoma Curcumae, Herb Gynostemmae Pentaphylli, Rhizoma Atractylodis Macrocephalae (parched), Poria, Radix Cynanchi Paniculati, Eupolyphaga Seu Steleophaga, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Massa Medicata Fermentata preparata decocte with water twice, 2 hours for the first time, 1 hour for the second time; Merging decoction liquor filters; Filtrating concentrates, and drying is ground into fine powder;
(4), with the dried cream powder flour facing-up of step (2) gained fine powder and step (3) gained, the mixing that sieves is processed pill by conventional method, promptly gets.
Embodiment 4:
For confirming the curative effect of Drug therapy of the present invention and prevention radiation damage, use the capsule content (to call medicine of the present invention in the following text) that makes by embodiment 1 method, carried out following pharmacological testing research:
Pharmaceutical composition of the present invention influences radiation damage mice hematopoietic function recovery
1 materials and methods
1.1 reagent and instrument:
Pharmaceutical composition effluent of the present invention north provides with mountain range Medicine Research Academy;
Instrument: U.S. Multiskan produces full-automatic ELIASA, CO
2Incubator (production of U.S. Forma company), the U.S. produce (IE USA) refrigerated centrifuger, superclean bench (Suzhou Decontamination Equipment Plant's production): remote control stomach and intestine machine (the Japanese DGW of Toshiba one 20A), radiation agent record are surveyed and employed China Testing Technology Institute product 9206 doses of record appearance, LPS is that U.S. Sigma product, MTT (tetrazolium bromide) are U.S. GIBCO Company products for FLUKA Company products, dimethyl sulfoxide (DMSO) for Suzhou chemical institute production, TPMI-1640.
1.2 animal divides into groups and administration:
36 of BALB/C mices, body weight 18-22g, male and female have concurrently, and licence numbering SCXK (capital) 2002-0003 is provided by Beijing Vital River Experimental Animals Technology Co., Ltd..Divide 3 groups at random with animal, 12 every group.The I group is physiology saline control normal group; The II group adds irradiation group for saline; The III group adds the irradiation experimental group for pharmaceutical composition of the present invention.I, II group is irritated stomach with normal saline every day, and 0.5ml/ time, 1 time/d, III organizes every day with medicine 3g crude drug/kg of the present invention, every day gastric infusion once.II, III organize in the capable systemic exposure x-ray bombardment of 30min behind the filling stomach in the 6th day, and with equivalent square field 18cm * 18cm, focus--Mus is apart from 80cm.Shine 0.11CGY every day, 1 time/d concurrent irradiation 5 times.
1.3 detect index and method
1.3.1 proliferation of bone marrow cells reaction
Mice is put to death in the cervical vertebra dislocation, and the bifilar bone medullary cell of mice is got by the sterile working, transfers cell concentration to 5 * 10
6/ ml gets 100 μ l and adds in the 96 porocyte culture plates, establishes 5 multiple holes, puts 37 ℃, 5%CO
2Cultivate 72h in the incubator, 5h before stopping mixes MTT (5mg/ml) 10 μ l/ holes, the centrifugal supernatant of abandoning when stopping cultivating, and every hole adds 100 μ l DMSO dissolving MTT reduzate Jia Za (Fonnazan) dissolving buffer, fully shakes 10min.Full-automatic ELIASA is surveyed the OD value with the 560nm wavelength, represents medullary cell active with the OD value.
1.3.2 quantitative haemolysis spectrophotometry (QHS)
The external B cell of this law produces the hemoglobin content (with the OD value representation) that the secretory antibody splitting erythrocyte is discharged, and its result can react the humoral immunity of organism function.Test and respectively 5% sheep red blood cell (SRBC) 0.2ml injection was respectively organized in the mouse peritoneal in the 5th day, eyeball blood-letting in the 11st day, the cervical vertebra dislocation causes death, and routine is got spleen, carries out the splenocyte counting then, transfers cell concentration to 1 * 10
7/ ml, extracting spleen cell 1ml, 1: 10 fresh GPS (complement) 1ml; 2% sheep red blood cell (SRBC) (SRBC) 1ml mixing, 37 ℃ of water-bath 1h, the centrifugal 10min of 1500r/m; Get supernatant and survey the A value in full-automatic ELIASA 450 nm wavelength, as the QHS response value with 96 porocyte culture plates.
1.4 the method for mean difference t check is carried out statistical analysis between statistical method experimental result employing group.
2 results
Chinese medicine composition of the present invention is seen table 1 to the influence that bone marrow cells in mice propagation, antibody produce
The influence that table 1 Chinese medicine composition of the present invention produces bone marrow cells in mice propagation antibody (X ± SD)
| Group | Proliferation of bone marrow cells | QHS |
| The I group | 0.589±0.046 | 0.599±0.073 |
| The II group | 0.298±0.021 ### | 0.357±0.039 ### |
| The III group | 0.572±0.048 #** | 0.583±0.019 #** |
Compare #P＜0.05, ###P＜0.001 with normal group (I group); Compare with irradiation group (II group),
*P＜0.001, n=12
More than experiment shows; Chinese medicine composition of the present invention can stimulate the generation of mouse antibodies, and the antibody-secreting amount is increased, and compares with irradiation group; Very significantly significant difference (P＜0.001) is arranged; Chinese medicine composition of the present invention has obvious facilitation to medullary cell increment, and compares with irradiation group, and very significantly significant difference (P＜0.001) is arranged.
This shows that Chinese medicine composition of the present invention has tangible radiation resistance, reconcile the effect that bone marrow hematogenesis and enhancing antibody produce.
Embodiment 5:
Pharmaceutical composition of the present invention is to the influence of radiation damage rat PBC and SOD in serum
1 materials and methods
1.1 reagent and instrument:
Pharmaceutical composition effluent of the present invention north provides with mountain range Medicine Research Academy;
Reagent and instrument: the SOD test kit is provided by Guangzhou exhibition bio tech ltd in morning.756 type ultraviolet spectrophotometers (Shanghai precision instrument science company limited).
1.2 animal divides into groups and administration:
The Wistar rat, male, body weight 170 ± 10g is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., licence numbering SCXK (capital) 2002-0003.Divide 3 groups at random with animal, 10 every group.The I group is the prevention group, reinstates Chinese medicine composition of the present invention in 3 days in pre-irradiation and irritates stomach, and dosage is 3g crude drug/kg; II group is the treatment group, begins administration, continuous 7 day the same day with same dosage in exposure; The III group is irradiation group, irritates clothes equivalent distilled water 7 days.Each group receives disposable total irradiation radiation gamma simultaneously, accumulated dose 3.0Gy, close rate 1.0Gy/min, irradiation 3min.
1.3 sampling
Laboratory animal is in pre-irradiation 1 day, according to back heart blood sampling in 1,4,7 day.The etherization rat, 75% ethanol disinfection rat chest is with about 2ml disposable syringe blood sampling 1ml.With leukocyte diluent (HCL: CH
3COOH=1: counting was respectively organized leukocyte count, 3000r/min, the non-anticoagulant separation of serum of 15min after 3) 0.38ml added 0.02ml whole blood mixing.
1.4 SOD measures
Adopt xanthine oxidase-hydroxylamine assay, utilize 756 type ultraviolet-uisible spectrophotometers to detect absorbance at wavelength 550nm place.
1.5 statistical disposition adopts SPSS 11.5 statistical softwares that experimental data is analyzed.
2 results
2.1 Chinese medicine composition of the present invention is seen influence (X ± SD, 1 * 10 of table 1 table 1 Chinese medicine composition of the present invention to exposure rat peripheral blood WBC to the influence of exposure rat peripheral blood WBC
5Cells)
| Group | According to preceding 1 day | According to back 1 day | According to back 4 days | According to back 7 days |
| Irradiation group | 12.9±1.40 | ?2.97±0.15 * | 0.49±0.05 * | 1.03±0.41 * |
| The prevention group | 12.9±3.50 | ?2.99±0.10 * | 0.84±0.04 *# | 1.42±0.36 *# |
| The treatment group | 12.8±5.90 | ?3.11±0.28 *# | 0.70±0.06 *# | 1.66±0.25 *# |
Annotate: with 1 day ratio of pre-irradiation,
*P＜0.05; Compare #P＜0.05 with irradiation group
Visible by table 1 to receiving according to the influence of rat peripheral blood WBC, WBC counting difference does not have significance between each processed group of pre-irradiation 1d; Irradiation back 1,4,7d respectively organize the WBC counting and compare with pre-irradiation remarkable decline is all arranged, and wherein reduce to minimumly according to back 4d, and 7d significantly gos up.Irradiation back each group difference of 1d does not have significance, irradiation back 4,7d, and pharmaceutical composition prevention group of the present invention is compared remarkable rising (P＜0.05) with treatment group WBC value with irradiation group.Dynamic observe in the process whole, prevention group and treatment group do not have significant difference.
2.2 Chinese medicine composition of the present invention is to receiving the influence according to rat blood serum SOD
Table 2 Chinese medicine composition of the present invention to receive according to rat blood serum SOD influence (X ± SD, U/ml)
| Group | According to preceding 1 day | According to back 1 day | According to back 4 days | According to back 7 days |
| Irradiation group | 155.4±12.1 | ?72.9±26.3 * | 88.0±46.8 * | 119.7±14.4 |
| The prevention group | 156.8±19.8 | ?122.1±18.7 # | 1?31.1±42.4 # | 142.7±10.4 |
| The treatment group | 152.6±11.8 | ?142.7±10.3 # | 132.6±52.9 # | 152.3±14.6 |
Annotate: with 1 day ratio of pre-irradiation,
*P＜0.05; Compare #P＜0.05 with irradiation group
Visible by table 2, pre-irradiation 1d, the SOD activity difference does not have significance between each processed group.According to back 1,4d, each is organized the SOD activity and compares all significantly decline with pre-irradiation.And irradiation group significantly is lower than prevention group and treatment group.According to back 7d, each organizes the SOD activation recovering near pre-irradiation, but irradiation group still is lower than prevention group and treatment group.
3, conclusion
After body was shone, because the indirect action of ionizing radiation can produce a large amount of free radicals, the character of free radical was very active; Can cause the number of chemical reaction; And can act on biomembrane generation lipid peroxidation, and peroxide injury is the starting point of many toxic actions, causes multiple pathological process.SOD is the antioxidase of topmost removing free radical, can effectively remove the superoxide anion that produces in the body, and stops free radical chain reactions.This experimental result shows that it is active that ionizing radiation can obviously reduce rat blood serum SOD, and Chinese medicine composition of the present invention has remarkable antagonism to the active decline of rat blood serum SOD due to the radiation.
Because blood system is relatively more responsive to radiation, after animal is shone, can cause that leukocyte descends rapidly.Originally experiment showed, and shine the forward and backward effect that Chinese medicine composition of the present invention all has promotion WBC recovery that gives, prompting has the dual function that prevents and treat for radiation damage.
Claims (8)
1. the application of Chinese medicine composition in the medicine of preparation treatment and prevention radiation injury is characterized in that being processed by following raw medicaments in portion by weight:
2. application according to claim 1 is characterized in that being processed by following raw medicaments in portion by weight:
3. application according to claim 1 is characterized in that being processed by following raw medicaments in portion by weight:
4. application according to claim 1 is characterized in that being processed by following raw medicaments in portion by weight:
5. according to each described application among the claim 1-4, it is characterized in that the active component of said Chinese medicine composition is processed by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Cordyceps, Radix Notoginseng pulverize separately become fine powder, sieving for standby;
(3), the Radix Astragali, Fructus Ligustri Lucidi, Ganoderma, Rhizoma Curcumae, Herb Gynostemmae Pentaphylli, Rhizoma Atractylodis Macrocephalae (parched), Poria, Radix Cynanchi Paniculati, Eupolyphaga Seu Steleophaga, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Massa Medicata Fermentata preparata decocte with water twice, 2 hours for the first time, 1 hour for the second time; Merging decoction liquor filters; Filtrating concentrates, and drying is ground into dried cream powder;
The common active ingredient that constitutes said Chinese medicine composition of step (2) gained fine powder and step (3) gained dried cream powder.
6. according to the arbitrary described application of claim 1-4, the preparation formulation that it is characterized in that said Chinese medicine composition is capsule, tablet, powder, oral liquid, pill, tincture, syrup, suppository, gel, spray or injection.
7. application according to claim 6, the method for preparing that it is characterized in that described capsule is to be processed by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Cordyceps, Radix Notoginseng pulverize separately become fine powder, sieving for standby;
(3), the Radix Astragali, Fructus Ligustri Lucidi, Ganoderma, Rhizoma Curcumae, Herb Gynostemmae Pentaphylli, Rhizoma Atractylodis Macrocephalae (parched), Poria, Radix Cynanchi Paniculati, Eupolyphaga Seu Steleophaga, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Massa Medicata Fermentata preparata decocte with water twice, 2 hours for the first time, 1 hour for the second time; Merging decoction liquor filters; Filtrating concentrates, and drying is ground into fine powder;
(4), with the comminuted powder facing-up of step (3) gained fine powder and step (2) gained, the mixing that sieves, encapsulated, promptly get.
8. according to each described application among the claim 1-4, it is characterized in that treatment and prophylaxis of tumours patient radiotherapy damage later on.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810055211XA CN101607059B (en) | 2008-06-20 | 2008-06-20 | Application of Chinese medicinal composition in preparing medicament for treating and preventing radiation injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810055211XA CN101607059B (en) | 2008-06-20 | 2008-06-20 | Application of Chinese medicinal composition in preparing medicament for treating and preventing radiation injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101607059A CN101607059A (en) | 2009-12-23 |
| CN101607059B true CN101607059B (en) | 2012-06-27 |
Family
ID=41481070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810055211XA Active CN101607059B (en) | 2008-06-20 | 2008-06-20 | Application of Chinese medicinal composition in preparing medicament for treating and preventing radiation injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101607059B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100729B (en) * | 2011-01-21 | 2012-07-25 | 中国人民解放军第四军医大学 | Oral administration medicament for treating and preventing radiation damage |
| CN102139021B (en) * | 2011-04-11 | 2012-07-04 | 扬州大学 | Chinese medicinal preparation for preventing and treating radiation and preparation method thereof |
| CN102166301B (en) * | 2011-04-21 | 2012-05-23 | 扬州大学 | Chinese herbal external cream for preventing and treating radiation and preparation method thereof |
| CN102357230B (en) * | 2011-11-01 | 2012-11-14 | 山东大学 | Traditional Chinese medicine preparation for treating radiation encephalopathy |
| CN102727567B (en) * | 2012-02-24 | 2014-10-01 | 广州加原医药科技有限公司 | Chinese medicine composition with radiation protecting function |
| CN104001149A (en) * | 2014-05-27 | 2014-08-27 | 刘存兵 | Traditional Chinese medicine composition for treating radiation injuries and preparation method thereof |
| CN106075479A (en) * | 2016-06-07 | 2016-11-09 | 陈萍 | A kind of contrast agent for gastrointestinal tract ultrasonic diagnosis and its preparation method and application |
| CN107126474B (en) * | 2017-03-24 | 2020-07-17 | 神威药业集团有限公司 | Application of qingkailing composition in preparation of medicine for treating and/or preventing radiation injury |
| CN112206298A (en) * | 2019-06-25 | 2021-01-12 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating diarrhea |
| CN114159462B (en) * | 2021-11-06 | 2023-02-03 | 中国人民解放军海军军医大学 | SiO 2 Application of the same in preparing anti-radiation medicine or medicine for treating ionizing radiation injury |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403147A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for raising body's immunity and its prepn |
| CN1488297A (en) * | 2003-07-28 | 2004-04-14 | 郑伟达 | Health food for cancer patient and preparing method thereof |
| CN1582995A (en) * | 2004-06-15 | 2005-02-23 | 河北以岭医药研究院有限公司 | Preparation of medicinal composition for nourishing |
-
2008
- 2008-06-20 CN CN200810055211XA patent/CN101607059B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403147A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for raising body's immunity and its prepn |
| CN1488297A (en) * | 2003-07-28 | 2004-04-14 | 郑伟达 | Health food for cancer patient and preparing method thereof |
| CN1582995A (en) * | 2004-06-15 | 2005-02-23 | 河北以岭医药研究院有限公司 | Preparation of medicinal composition for nourishing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101607059A (en) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101607059B (en) | Application of Chinese medicinal composition in preparing medicament for treating and preventing radiation injury | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN101284050B (en) | Corydalis tuber water soluble part medicament and its preparation method and application | |
| CN101732668A (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN113209166A (en) | Anti-aging traditional Chinese medicine composition containing nicotinamide mononucleotide and preparation method thereof | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN100558379C (en) | Shuang Huang Lian ' dispersible tablet and preparation method thereof | |
| US7381430B2 (en) | Pharmaceutical composition comprising a combination of Chinese traditional medicines | |
| CN108126011B (en) | Pharmaceutical composition for auxiliary conditioning of patients undergoing tumor radiotherapy and chemotherapy and preparation method thereof | |
| CN103599265B (en) | A kind of compound traditional Chinese medicine for radiation protection | |
| CN101468056B (en) | Chinese medicine preparation for treating enteritis, diarrhea, and red-white dysentery | |
| CN101259180B (en) | Shenshe composition and preparation thereof | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN1943661A (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN110448631A (en) | A kind of children massage with kidney tonifying cream and preparation method thereof | |
| CN107802681B (en) | Composition for improving clinical symptom sign of HIV infected person | |
| CN102225155A (en) | Medicament composition for treating pulmonary fibrosis | |
| CN103800844B (en) | A kind of pharmaceutical composition for the treatment of acute pancreatitis and preparation method thereof | |
| CN102430040A (en) | Medicament for treating diabetes | |
| CN102058668A (en) | Traditional Chinese medicinal preparation for treating primary thrombocytopenia | |
| CN100528218C (en) | Pharmaceutical composition, its preparation process and usage | |
| CN1931352A (en) | Chinese medicine composition and its prepn process | |
| CN104189846A (en) | Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof | |
| CN117205266A (en) | Pharmaceutical composition for reducing ionizing radiation hazard |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |